药物治疗慢性粒细胞白血病成本-效果的系统评价
作者：王璇;陈岷;胡明;张伶俐;
Author：
收稿日期： 年卷（期）页码：2009,24(03):-325-326
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：慢性粒细胞白血病;伊马替尼;干扰素-α
Key words：
基金项目：四川省卫生厅科研项目(070184)
中文摘要
比较并评价治疗慢性粒细胞白血病(CML)药物的成本-效果,为临床合理用药提供依据。
参考文献
[1]王强,张成刚,李大魁,等.伊马替尼用于慢性粒细胞性白血病治疗的药物经济学评价[J].中国药学杂志,2005,40(6):472-474.
[2]Warren E,Ward S,Gordois A,et al.Cost-utility analysis of ima-tinib mesylate for the treatment of chronic myelogenous leukemiain the chronic phase[J].Clin Therapeut,2004,26(11):1924-1933.
[3]Kattan MW,Inoue Y,Giles FJ,et al.Cost-effectiveness of in-terferon-alpha and conventional chemotherapy in chronic my-elogenous leukemia[J].Ann Intern Med,1996,125(7):541-548.
[4]Lee SJ,Anasetti C,Kuntz KM,et al.The costs and cost-effec-tiveness of unrelated donor bone marrowtransplantation for chron-ic phase chronic myelogenous leukemia[J].Blood,1998,92(11):4047-4052.
[5]Gordois A,Scuffham P,Warren E,et al.Cost-utility analysis ofimatinib mesylate for the treatment of advanced stage chronic my-eloid leukemia[J].Bri J Canc,2003,89(4):634-640.
[6]Anstrom KJ,Reed SD,Allen AS,et al.Long-term survival esti-mates for imatinib versus interferon-alpha plus low-dose cyt-arabine for patients with newly diagnosed chronic-phase chronicmyeloid leukemia[J].Cancer,2004,101(11):2584-2592.
【关闭】
